首页 | 本学科首页   官方微博 | 高级检索  
     


Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study
Authors:C. W. Francis  C. M. Kessler  S. Z. Goldhaber  M. J. Kovacs  M. Monreal  M. V. Huisman  D. Bergqvist  A. G. Turpie  T. L. Ortel  A. C. Spyropoulos  I. Pabinger  A. K. Kakkar
Affiliation:1. University of Rochester Medical Center, Rochester, NY, USA;2. Georgetown University Hospital, Washington, DC, USA;3. Brigham and Women's Hospital, Boston, MA, USA;4. London Health Sciences Centre, London, Ontario, Canada;5. Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, Barcelona, Spain;6. Leiden University Medical Center, Leiden, the Netherlands;7. University Hospital, Uppsala, Sweden;8. Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada;9. Duke University Medical Center, Durham, NC, USA;10. Medical University of Vienna, Wien, Austria;11. Barts and The London Queen Mary's School of Medicine and Dentistry, London, UK
Abstract:
Keywords:cancer  dalteparin  deep vein thrombosis  low‐molecular‐weight heparin  pulmonary embolism  venous thromboembolism
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号